Industry News
Pharmaceutical Industry News
Vectura to choose next owner after Carlyle, Philip Morris submit final bids: report
Vectura to choose next owner after Carlyle, Philip Morris submit final bids: report fkansteiner Wed, 08/11/2021 - 09:34
Perfect packaging? J&J’s latest innovation challenge crowdsources single dose ideas
Perfect packaging? J&J's latest innovation challenge crowdsources single dose ideas bbulik Tue, 08/10/2021 - 16:14
Teva, Glenmark accuse U.S. government of improperly expanding price-fixing case
Teva, Glenmark accuse U.S. government of improperly expanding price-fixing case kdunleavy Tue, 08/10/2021 - 11:30
Novartis, Pfizer and Gilead roll out COVID-19 vaccination rules as Delta makes case for mandates
Novartis, Pfizer and Gilead roll out COVID-19 vaccination rules as Delta makes case for mandates fkansteiner Tue, 08/10/2021 - 11:29
UPDATED: Novartis, Pfizer and Gilead roll out COVID-19 vaccination rules as delta makes case for mandates
UPDATED: Novartis, Pfizer and Gilead roll out COVID-19 vaccination rules as delta makes case for mandates fkansteiner Tue, 08/10/2021 - 11:29
Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering. But anxiety grows over outlook for biologics
Merck, Novo, Sanofi and more pull off China growth thanks to price maneuvering. But anxiety grows over outlook for biologics aliu Tue, 08/10/2021 - 10:57
J&J matches Stelara’s ‘Bold’ message to the Olympic spirit in TV media buy during Tokyo games
J&J matches Stelara’s ‘Bold’ message to the Olympic spirit in TV media buy during Tokyo games bbulik Tue, 08/10/2021 - 10:56
Inflammasome gets Gates grant for dual HIV-birth control implant
Inflammasome gets Gates grant for dual HIV-birth control implant ntaylor Tue, 08/10/2021 - 09:32
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the UK. Could the next big ‘sartan’ recall be on the horizon?
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the UK. Could the next big 'sartan' recall be on the horizon? fkansteiner Tue, 08/10/2021 - 09:25
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the U.K. Could the next big ‘sartan’ recall be on the horizon?
Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the U.K. Could the next big 'sartan' recall be on the horizon? fkansteiner Tue, 08/10/2021 - 09:25
Moderna lays plans for new Canadian mRNA vaccine manufacturing site—and more could be on the way
Moderna lays plans for new Canadian mRNA vaccine manufacturing site—and more could be on the way nhigginsdunn Tue, 08/10/2021 - 09:09
Viatris shows no signs of growing pains in its ‘trough year,’ but one analyst has longer-term worries
Viatris shows no signs of growing pains in its 'trough year,' but one analyst has longer-term worries kdunleavy Tue, 08/10/2021 - 07:06
Regeneron scraps sustained-release Eylea alliance with Ocular
Regeneron scraps sustained-release Eylea alliance with Ocular ntaylor Tue, 08/10/2021 - 05:51
Oyster Point sells China rights to nasal sprays for eye disease
Oyster Point sells China rights to nasal sprays for eye disease ntaylor Tue, 08/10/2021 - 05:47
Eyevensys bags $12M to test non-viral gene therapy delivery tech
Eyevensys bags $12M to test non-viral gene therapy delivery tech ntaylor Tue, 08/10/2021 - 05:44
J&J’s Ponvory may be late to the multiple sclerosis market, but doctors still see potential: study
J&J's Ponvory may be late to the multiple sclerosis market, but doctors still see potential: study bbulik Mon, 08/09/2021 - 16:20
Ginkgo and Aldevron tout mRNA manufacturing ‘breakthrough’—and the perks could stretch well beyond COVID-19, exec says
Ginkgo and Aldevron tout mRNA manufacturing 'breakthrough'—and the perks could stretch well beyond COVID-19, exec says fkansteiner Mon, 08/09/2021 - 16:05
Biohaven’s Nurtec ODT outmuscles AbbVie’s Ubrelvy in gaining new migraine patients following key FDA nod
Biohaven's Nurtec ODT outmuscles AbbVie's Ubrelvy in gaining new migraine patients following key FDA nod nhigginsdunn Mon, 08/09/2021 - 12:01
With the pricing situation ‘untenable’ in Europe, Bluebird will wind down its operations in the ‘broken’ market
With the pricing situation 'untenable' in Europe, Bluebird will wind down its operations in the 'broken' market kdunleavy Mon, 08/09/2021 - 11:33
BioNTech, eyeing $18B-plus in COVID-19 vaccine sales this year, poised to join the ranks of the world’s top drugmakers
BioNTech, eyeing $18B-plus in COVID-19 vaccine sales this year, poised to join the ranks of the world's top drugmakers fkansteiner Mon, 08/09/2021 - 11:17